Our new profile is- Sophiris Bio, Inc. (NASDAQ:SPHS)
Earnings due out possibly today, although the potential for their drug pipeline out weighs current earnings
Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of Concept Study in Localized Prostate Cancer
Analyst strong Buy- http://www.nasdaq.com/symbol/sphs/recommendations
Wall Street analysts covering shares of Sophiris Bio, Inc. (NASDAQ:SPHS) have recently chimed in on the stock. Compiling all of the price targets issued by equity research firms have yielded a consensus target of $5.00/share. This is according to First Call data compiled by Thomson Reuters.
Past and future earnings growth are also important indicators in determining where the stock might be headed. Analysts are predicting $0.0000 per share in earnings next quarter and $-0.9500 for the current year. In comparing the current price level of the equity to their moving averages, the shares are trading -0.0913 off of the 50-day average of $1.8006 and 0.1963 away from the 200-day moving average of $1.5130.
Another important factor to consider when evaluating a stock’s current and future value are the 52 week high and low levels. As of the most recent bid at the time of writing, Sophiris Bio, Inc. shares are trading -55.6026% away from the 52-week high mark of 3.8500 and +256.1042% off the 52-week bottom of 0.4800.
Taking a step further, investors might also consider evaluating a firm’s PEG ratio, which illustrates the relationship between stock price, earning per share, and the company’s growth rate. A firm with a PEG ratio below 1 is considered undervalued. A company with a PEG ratio around 1 is considered fairly valued. A company with a PEG ratio greater than 1 is considered overvalued. The stock has a current PEG of 0.0000.
Consensus from NASDAQ.com
Sources: wall street analyst, uptick analyst, Broad street Alerts, Nasdaq.com
SCS LLC and broad street alerts have not been compensated for the mention of SPHS and we do not hold any positions.